申请人:ChemoCentryx, Inc.
公开号:US10744118B2
公开(公告)日:2020-08-18
Compounds are provided that act as potent antagonists of the CCR1 receptor, and have in vivo anti-inflammatory activity. The compounds are diazole lactam derivatives and are useful in pharmaceutical compositions, methods for the treatment of CCR1-mediated disease, and as controls in assays for the identification of competitive CCR1 antagonists.
所提供的化合物可作为 CCR1 受体的强效拮抗剂,并具有体内抗炎活性。这些化合物是重氮内酰胺衍生物,可用于药物组合物、治疗 CCR1 介导的疾病的方法,并可在鉴定竞争性 CCR1 拮抗剂的试验中用作对照。